Centuri Holdings (CTRI) Reports Q1 Loss, Tops Revenue Estimates — Negative

CTRI   Zacks Investment Research — May 12, 2025

Centuri Holdings (CTRI) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $137.53 per share a year ago.

image for news Centuri Holdings (CTRI) Reports Q1 Loss, Tops Revenue Estimates

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates — Negative

CRVO   Zacks Investment Research — May 12, 2025

CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.

image for news CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates — Negative

URGN   Zacks Investment Research — May 12, 2025

Urogen Pharma (URGN) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.97 per share a year ago.

image for news Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates

What Analyst Projections for Key Metrics Reveal About Cava (CAVA) Q1 Earnings — Positive

CAVA   Zacks Investment Research — May 12, 2025

Besides Wall Street's top -and-bottom-line estimates for Cava (CAVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

image for news What Analyst Projections for Key Metrics Reveal About Cava (CAVA) Q1 Earnings

Take-Two (TTWO) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates — Neutral

TTWO   Zacks Investment Research — May 12, 2025

Evaluate the expected performance of Take-Two (TTWO) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

image for news Take-Two (TTWO) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Fox Corporation (FOX) Surpasses Q3 Earnings and Revenue Estimates — Positive

FOX   Zacks Investment Research — May 12, 2025

Fox Corporation (FOX) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.09 per share a year ago.

image for news Fox Corporation (FOX) Surpasses Q3 Earnings and Revenue Estimates

Unlocking Q2 Potential of Deere (DE): Exploring Wall Street Estimates for Key Metrics — Positive

DE   Zacks Investment Research — May 12, 2025

Beyond analysts' top -and-bottom-line estimates for Deere (DE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended April 2025.

image for news Unlocking Q2 Potential of Deere (DE): Exploring Wall Street Estimates for Key Metrics

Curious about Walmart (WMT) Q1 Performance? Explore Wall Street Estimates for Key Metrics — Positive

WMT   Zacks Investment Research — May 12, 2025

Beyond analysts' top -and-bottom-line estimates for Walmart (WMT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended April 2025.

image for news Curious about Walmart (WMT) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Applied Materials (AMAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended April 2025.

image for news Seeking Clues to Applied Materials (AMAT) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148081&wire=1 or contact Joseph E. Levi, Esq.

image for news Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Civitas Resources, Inc. (NYSE:CIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/civitas-resources-lawsuit-submission-form?prid=148082&wire=1 or contact Joseph E. Levi, Esq.

image for news Levi & Korsinsky Notifies Shareholders of Civitas Resources, Inc. (CIVI) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=148085&wire=1 or contact Joseph E. Levi, Esq.

image for news Shareholders That Lost Money on Open Lending Corporation (LPRO) Should Contact Levi & Korsinsky About Pending Class Action - LPRO

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.

image for news Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.

image for news Organon & Co. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OGN

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cable One, Inc. ("Cable One, Inc.") (NYSE:CABO) concerning possible violations of federal securities laws. On May 2, 2025, Cable One missed earnings expectations by nearly $8 and suspended its dividend.

image for news Investors Who Lost Money on Cable One, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - CABO

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148079&wire=1 or contact Joseph E. Levi, Esq.

image for news Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) Shareholders

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=148080&wire=1 or contact Joseph E. Levi, Esq.

image for news TFI International Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 13, 2025 to Discuss Your Rights - TFII

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.

image for news Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Fluence Energy, Inc. (NASDAQ:FLNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=148084&wire=1 or contact Joseph E. Levi, Esq.

image for news Contact Levi & Korsinsky by May 12, 2025 Deadline to Join Class Action Against Fluence Energy, Inc. (FLNC)

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=148083&wire=1 or contact Joseph E. Levi, Esq.

image for news Levi & Korsinsky Notifies Shareholders of Ibotta, Inc. (IBTA) of a Class Action Lawsuit and an Upcoming Deadline